Supportive Care: Growth Factors

Phase 2Small molecule

CCenter for International Blood and Marrow Transplant Research

Supportive Care: Growth Factors is one of 5 small molecule programs targeting Peripheral Blood Stem Cell Transplantation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Blood Stem Cell TransplantationRecruiting

Peripheral Blood Stem Cell TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Peripheral Blood Stem Cell Transplantation

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Phase 3

2 2

Prograf

VVeloxis Pharmaceuticals

Phase 3

3 3

Velcade

SShilpa Grover, MD, MPH

Phase 2

2 4

Supportive Care: Growth Factors

CCenter for International Blood and Marrow Transplant Research

Phase 2

1 5

Darzalex

Qilu Pharmaceutical Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Peripheral Blood Stem Cell Transplantation

NCT06859424

Clinical

Trials by Indication[1]

Peripheral Blood Stem Cell Transplantation1 trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Recruiting·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT06859424·358 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Supportive Care: Growth Factors. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Supportive Care: Growth Factors compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Supportive Care: Growth Factors. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Center for International Blood and Marrow Transplant Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCenter for International Blood and Marrow Transplant Research

Supportive Care: Growth Factors

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Peripheral Blood Stem Cell Transplantation1 trial

References

Drug Info

Quick Facts

Related News